Myeloma Minute: August 27, 2015
Daratumumab Shows 36% Efficacy Rate in Treating Relapsed and Refractory Multiple Myeloma in Study
A study published in the New England Journal of Medicine today announced that daratumumab, a monoclonal antibody, has shown favorable treatment results in phase 1 and phase 2 trials for patients with relapsed or refractory myeloma. According to the study and a press release issued by daratumumab manufacturers Genmab and Johnson & Johnson, the data showed a 36% response rate in the group treated in phase two of the study and furthermore, 65% of those patients had not experienced disease progression in the 12 months after the start of treatment. Read Dr. Durie’s commentary on the study, HERE.
2 Top Medical Journals Weigh in on Potential Danger of Toxic Chemicals
Reports in two highly respected medical journals—the Lancet and the New England Journal of Medicine—agree that weed killers used with genetically modified crops (commonly known as GMOs), such as corn and soybeans, cause cancer. In his blog this week, IMF Chairman Dr. Brian Durie writes that in light of the evidence, it’s vitally important for consumers to know what’s in their food. To read, click HERE.
Expanded Access Program for Elotuzumab
An Expanded Access Program (EAP) for elotuzumab with lenalidomide (Revlimid®) and dexamethasone is now open for myeloma patients with relapsed or refractory multiple myeloma. Elotuzumab is the first monoclonal antibody developed to treat multiple myeloma. Clinical trials have provided insights that elotuzumab works more effectively in combination with the immunomodulatory agent Revlimid and the steroid dexamethasone than alone. To learn more about the elotuzumab EAP, read the IMF’s Clinical Trial Fact Sheet, HERE.
Watch the IMF Patient & Family Seminar Live Stream Replay on IMF TV
For those who weren’t able to attend the IMF Patient & Family Seminar in Los Angeles last weekend, there is a live stream replay now available on IMF TV. Get the latest information on myeloma and watch presentations from many of the top myeloma experts, including a welcome and overview from IMF President Susie Novis and an explanation of “Myeloma 101” from IMF Chairman Dr. Brian Durie. To watch the replay, please click HERE.
Join the IMF's 9th Annual Comedy Celebration and Support Myeloma Research
The IMF 9th Annual Comedy Celebration is fast approaching!This year's gala is being headlined by actor and comedian Kevin Nealon and Late Show Band Leader Paul Shaffer will be leading the music portion of the evening. Proceeds will benefit the Peter Boyle Research Fund, as well as support the Black Swan Research Initiative, the IMF's groundbreaking and collaborative project aimed at developing the first definitive cure for myeloma. The gala event will kick off at 6 pm, Saturday, October 10 at the Wilshire Ebell Theatre & Club in Los Angeles. You can purchase tickets HERE.